Brian P. O'Connor - Center for Genes, Environment, and Health, National Jewish Health

基本信息

浏览量：58

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 25 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Phase II Open-Label Trial of Brentuximab Vedotin with Pembrolizumab in PD-1-Pretreated Metastatic Non-Small Cell Lung Cancer and Metastatic Cutaneous Melanoma

Sylvia M Lee,Omid Hamid,Robert Jotte,Yousef Zakharia,Theresa Medina,Amanda Gillespie-Twardy,Inderjit Mehmi,Sunandana Chandra, Graham Watson, Patrick Ward,Marya Chaney,Hailing Lu,Jason Berndt,Brian P O'Connor, Kapil Rathi, Eeman Shaikh,Charles Lance Cowey

Clinical cancer research an official journal of the American Association for Cancer Researchno. 5 (2025): 848-859

引用0浏览0WOS引用

799 Vedotin ADCs Reinvigorate Anti-Tumor Immunity in a Preclinical Model of Anti-Pd1 Resistance

David R Gruber,Weiping Zeng,Brian P O’Connor, Greg Szeto, Aakash Sur,Elizabeth E Gray,Alyson J Smith

Regular and Young Investigator Award Abstracts (2024)

引用0浏览0引用

1057 Sigvotatug Vedotin May Eliminate TGFβ-dependent Immunosuppression in the Tumor Microenvironment by Eliminating Integrin-Β6 (IB6) Expressing Cells, but Not Through Direct TGFβ Signaling Blockade

Chun-Shu Wong, Chuan Bian Lim,Roma Yumul,Bryan M Grogan,Michelle L Ulrich,Devra Olson,Li-Ya Huang,Kelly Hensley, Greg Stacey, Gina LoMastro,Rebecca Mazahreh, Serena Wu,Brian P O’Connor,Sharsti Sandall,Ryan A Heiser, Vivian Trang

Regular and Young Investigator Award Abstracts (2024)

引用0浏览0引用

1155 Activated Regulatory T Cells in Solid Tumors Express CD30, Which Are Selectively Targeted by the Novel Anti-Cd30 Antibody Drug Conjugate SGN-35T

Hailing Lu,Brian P O’Connor,Ryan A Heiser,Jason D Berndt,Michelle L Ulrich,Bryan M Grogan,Reice D James, Melissa Conerly,Astrid Clarke,Kevin J Hamblett

Journal for ImmunoTherapy of Cancer（2023）

引用0浏览0引用

699 Phase 2 Trial of Brentuximab Vedotin (BV) with Pembrolizumab (pembro) in Patients with Metastatic Non-Small Cell Lung Cancer or Metastatic Cutaneous Melanoma after Progression on Anti-Pd-1 Therapy

Omid Hamid,Sylvia Lee,Hailing Lu,Sunandana Chandra,Yousef Zakharia,Inderjit Mehmi,Marya Chaney, Graham Watson,Patrick Ward,Brian P O’Connor,Robert M Jotte,Amanda Gillespie-Twardy,Jason D Berndt, Kapil Rathi, Scott Knowles, Charles Cowey

Journal for ImmunoTherapy of Cancerno. Suppl 1 (2023)

引用0浏览0引用

A Preclinical Model of Acquired Anti-Pd-1 Resistance is Responsive to SEA-TGT, an Effector-Function Enhanced Anti-Tigit Monoclonal Antibody

David R. Gruber,Weiping Zeng, Bob Thurman,Brian P. O'Connor,Shyra J. Gardai,Alyson J. Smith

Cancer Researchno. 7_Supplement (2023): 6361-6361

引用1浏览0引用

SGN-BB228, a CD228-directed Costimulatory Antibody Anticalin® Bispecific Provides Potent and Conditional 4-1BB Costimulation to T Cells in Vivo and in an in Vitro Model of T Cell Exhaustion

Barrett Updegraff, Johannes Urban,James Mutschler,Gregory L. Szeto,Brian P. O'Connor,Shyra J. Gardai,Ryan A. Heiser

CANCER RESEARCHno. 7 (2023)

引用0浏览0引用

CD30 is a Marker of Activated Effector Regulatory T Cells in Solid Tumors Providing Clinical Rationale for the Combination of Brentuximab Vedotin and PD-1 Inhibitors

Ryan A. Heiser,Bryan M. Grogan,Reice D. James,Michelle L. Ulrich,Jason D. Berndt,Brian P. O'Connor,Shyra J. Gardai,Hailing Lu,Scott M. Knowles

Cancer Researchno. 7_Supplement (2023): 3253-3253

引用2浏览0引用

Novel Protein Pathways in Development and Progression of Pulmonary Sarcoidosis

Maneesh Bhargava,K. J. Viken,B. Barkes,T. J. Griffin,M. Gillespie,P. D. Jagtap,R. Sajulga,E. J. Peterson,H. E. Dincer,L. Li,C. I. Restrepo,B. P. O’Connor,T. E. Fingerlin,D. M. Perlman,L. A. Maier

Scientific Reports（2020）

引用22浏览0WOSNATURE引用

OPTIMIZING SINGLE-CELL RNA SEQUENCING FOR CF HUMAN IMMUNOLOGY STUDIES

N. Rysavy,K. Poch,S. Caceres, C. Laborda, F. Leti,K. Walton,K. Hisert,T. Fingerlin,B. O'Connor, K. Anderson,B. Vestal,R. Reinhardt,M. T. Saavedra

PEDIATRIC PULMONOLOGY（2020）

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn